EGFR and lung carcinoma: A previous study performed sensitivity screening of 94 lung cancer cell lines against NGI-1, the targeted inhibitor of oligo-saccharyl-transferase (OST), and reported that mutant EGFR was more sensitive to the inhibitor, and OST inhibition caused cell cycle arrest and also inhibited the expression of other EGFR co-expressed receptors, such as the mesenchymal–epithelial transition factor, thereby inhibiting the growth of tumor cells [142].